文献速递泌尿生殖腹部MRUS

认知融合靶向活检中mpMRI感兴趣区在超声上的可见性可预测前列腺癌检出:一项前瞻性单中心研究

Visibility of mpMRI region of interest on ultrasound during cognitive fusion targeted biopsy predicts prostate cancer detection: a prospective single-center study.
PubMed 文献 · Abdom Radiol (NY) · 2024-12-23

该前瞻性单中心研究分析了2023至2024年426例男性502个PI-RADS≥3病灶,在mpMRI/TRUS认知融合靶向活检中按超声特征分为良性/不可见(Bi)、仅低回声(Ho)和低回声伴微钙化(Hm),发现Ho和Hm是临床显著前列腺癌的独立预测因素。

要点

  • PI-RADS 3中Bi病灶非癌率64%(103/161),Ho+Hm病灶在PI-RADS 5中csPCa率最高达82%(102/124)。
  • Ho+Hm病灶主要见于PI-RADS 5(92%[114/124])和外周带(64%[179/278])。
  • Hm病灶筛状形态比例显著高于Ho病灶(32% vs 14%,P=0.001);多因素分析Ho(OR 4.95,P<0.001)和Hm(OR 27.7,P<0.001)均为csPCa独立预测因素。

核心结论

  • 在认知融合靶向活检中,TRUS上识别Ho和Hm病灶较Bi病灶能更精准定位,从而提高csPCa诊断率。

研究设计与样本

  • 前瞻性单中心研究,纳入2023至2024年426例男性的502个PI-RADS≥3病灶,均行靶向联合系统活检,参考标准为mpMRI/TRUS认知融合靶向活检。

关键影像表现/征象

  • 病灶按超声特征分为良性或不可见(Bi)233个(46%)、仅低回声(Ho)210个(42%)、低回声伴微钙化(Hm)59个(12%)。
  • Ho+Hm病灶主要分布于PI-RADS 5(92%[114/124])和外周带(64%[179/278])。

诊断标准与关键数值

  • PI-RADS 3中Bi病灶非癌率为64%(103/161)。
  • PI-RADS 5中Ho+Hm病灶csPCa率最高为82%(102/124)。
  • Hm病灶筛状形态比例32% vs Ho病灶14%(P=0.001)。
  • 多因素分析:Ho vs Bi的OR 4.95(P<0.001);Hm vs Bi的OR 27.7(P<0.001)。

临床应用与阅片要点

  • 活检时在TRUS上识别Ho和Hm病灶有助于更精准定位,从而提高csPCa诊断率。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: The purpose of this study was to evaluate the nature of ultrasound characteristics during mpMRI/TRUS cognitive fusion targeted biopsy (cTB).

METHODS: From 2023 to 2024, data from 502 lesions in 426 men who underwent targeted combined systematic biopsy were analyzed. All lesions had a Prostate Imaging Reporting and Data System (PI-RADS) score of ≥ 3. The primary endpoint was the detection rate of prostate cancer (PCa) according to the PI-RADS score/ultrasound characteristics, categorized as benign or invisible (Bi), hypoechoic only (Ho), and hypoechoic with microcalcification (Hm), assessed through cross-stratification. The secondary endpoints included the distribution of ultrasound characteristics across PI-RADS scores, prostate zones, and histological types. Finally, associations between ultrasound characteristics and clinically significant PCa (csPCa) were assessed using multivariate logistic regression analysis (MVA).

RESULTS: Among lesions, 233 (46%) were Bi, 210 (42%) Ho, and 59 (12%) Hm. First, Bi lesions had a 64% (103/161) non-cancer rate in PI-RADS 3, while Ho + Hm lesions showed the highest csPCa rate in PI-RADS 5 at 82% (102/124). Additionally, Ho + Hm lesions were predominantly observed in PI-RADS 5 (92% [114/124]) and in the peripheral zone (64% [179/278]). Notably, Hm lesions had a significantly higher percentage of cribriform morphology than Ho lesions (32% vs. 14%, P = 0.001). Finally, MVA confirmed Ho ([Ref Bi] OR 4.95, P < 0.001) and Hm ([Ref Bi] OR 27.7, P < 0.001) as independent predictors of csPCa.

CONCLUSION: In cTB, the identification of Ho and Hm lesions on TRUS enhances the diagnostic yield of csPCa by facilitating more precise localization compared to Bi lesions.

CLINICAL TRIAL REGISTRATION: No. 2023-272-002, July 14, 2023.

来源:Abdom Radiol (NY),查看原文。版权归原作者所有。

引用

  1. Qin F, Liu Z, Ma J, et al. Visibility of mpMRI region of interest on ultrasound during cognitive fusion targeted biopsy predicts prostate cancer detection: a prospective single-center study. Abdom Radiol (NY). 2024. PMID: 39710761. doi:10.1007/s00261-024-04750-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。